AQR Capital Management
BLPH

AQR Capital Management’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

AQR Capital Management’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-34,071
Closed -$347K – 2318
2020
Q3 		$347K Buy
+34,071
New +$401K ﹤0.01% 1868

Other funds holding BLPH

NMVA
New Mountain Vantage Advisers New York $4.33B AUM 35.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management's BLPH Position: Q4 2020 in Review

AQR Capital Management sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q4 2020, closing a stake of 34,071 shares — an estimated $347K sold.

AQR Capital Management first reported a position in BLPH in Q3 2020 and held it in 1 quarter. The position peaked at $347K in Q3 2020. 37 funds tracked by Wall St. Rank hold BLPH as of Q4 2020.

  • AQR Capital Management reported no remaining Bellerophon Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • AQR Capital Management sold 34,071 Bellerophon Therapeutics, Inc. shares in Q4 2020, an estimated $347K.
  • AQR Capital Management first reported a position in Bellerophon Therapeutics, Inc. in Q3 2020 and held it in 1 quarter.
  • AQR Capital Management's Bellerophon Therapeutics, Inc. position peaked at $347K in Q3 2020.
  • 37 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q4 2020.

Based on AQR Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.